Drug Profile
Research programme: Alzheimer's therapeutics - Qantu
Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Qantu Therapeutics
- Class Alzheimer vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 May 2020 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 28 May 2020 No recent reports of development identified for research development in Alzheimer's-disease(Prevention) in USA
- 25 Feb 2019 Qantu Therapeutics has patent protection for QT 0101 in USA